Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287256 · ClinicalTrials.gov registry record · Phase 1
Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05287256: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT05287256 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05287256, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The current study will investigate the subjective, physiological, and cognitive performance effects of inhaled and orally ingested Delta-8 tetrahydrocannabinol (THC) in comparison to both placebo and Delta-9 THC. The purpose of this study is to assess the effects of Delta-8 THC as compared to placebo and Delta-9 THC. Oral fluid, urine, blood, and hair specimens will be collected from participants.
Interventions
- DRUG Oral Placebo
- DRUG Oral Delta-8-THC Cannabis
- DRUG Oral Delta-9-THC Cannabis
- DRUG Vaporized Delta-8-THC Cannabis
- DRUG Vaporized Delta-9-THC Cannabis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2024-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05287256
The ClinicalTrials.gov registry entry for NCT05287256 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Oral Placebo is the first listed.
NCT05287256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05287256 about?
NCT05287256 is a clinical study titled "Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC". The current study will investigate the subjective, physiological, and cognitive performance effects of inhaled and orally ingested Delta-8 tetrahydrocannabinol (THC) in comparison to both placebo and Delta-9 THC. The purpose of this study is to assess the effects of Delta-8 THC as compared to placeb...
What is the current status of trial NCT05287256?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-05-23. Estimated completion is 2024-10-02.
What interventions are being tested in trial NCT05287256?
The interventions under investigation include: Oral Placebo (DRUG), Oral Delta-8-THC Cannabis (DRUG), Oral Delta-9-THC Cannabis (DRUG), Vaporized Delta-8-THC Cannabis (DRUG), Vaporized Delta-9-THC Cannabis (DRUG).
Who is sponsoring clinical trial NCT05287256?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.